# Selumetinib and Olaparib in Solid Tumors

> **NCT03162627** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 90 (estimated)

## Conditions studied

- Malignant Neoplasm of Breast
- Malignant Neoplasms of Digestive Organs
- Malignant Neoplasms of Female Genital Organs
- Malignant Neoplasms of Male Genital Organs
- Malignant Neoplasms of Thyroid and Other Endocrine Glands

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03162627
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-04
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162627, "Selumetinib and Olaparib in Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03162627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*